Base line characteristics of study population
| n | 32 |
| Men | 17 (53.1%) |
| Smoke | 8 (25.0%) |
| Oral contraceptive | 6 (40.0%)* |
| Arachidonic acid − | 5 (15.6%) |
| Age (mean ± SD) | 36.9 ± 11.2 (years) |
| Platelet vWF (mean ± SD) | 4.2 ± 1.1 (μg/1011 plt) |
| Plasma vWF (mean ± SD) | 9.7 ± 4.3 (μg/mL) |
| Total magnesium (mean ± SD) | 0.81 ± 0.09 (mmol/L) |
| Mg2+(mean ± SD) | 0.39 ± 0.04 (mmol/L) |
| ADP (mean ± SD) | 3.2 ± 0.8 (μg/1011 plt) |
| ATP (mean ± SD) | 6.0 ± 1.1 (μg/1011 plt) |
| ADP/ATP (mean ± SD) | 1.9 ± 0.3 |
| n | 32 |
| Men | 17 (53.1%) |
| Smoke | 8 (25.0%) |
| Oral contraceptive | 6 (40.0%)* |
| Arachidonic acid − | 5 (15.6%) |
| Age (mean ± SD) | 36.9 ± 11.2 (years) |
| Platelet vWF (mean ± SD) | 4.2 ± 1.1 (μg/1011 plt) |
| Plasma vWF (mean ± SD) | 9.7 ± 4.3 (μg/mL) |
| Total magnesium (mean ± SD) | 0.81 ± 0.09 (mmol/L) |
| Mg2+(mean ± SD) | 0.39 ± 0.04 (mmol/L) |
| ADP (mean ± SD) | 3.2 ± 0.8 (μg/1011 plt) |
| ATP (mean ± SD) | 6.0 ± 1.1 (μg/1011 plt) |
| ADP/ATP (mean ± SD) | 1.9 ± 0.3 |
% women.